Aim high - Adjuvant interferon in melanoma (high risk): No confirmation yet that low dose interferon is of benefit

Slični predmeti

• Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
  od: Hancock, B, i dr.
  Izdano: (2004)
• Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
  od: Mia Salans, i dr.
  Izdano: (2021-10-01)
• Adjuvant therapy of melanoma with interferon: lessons of the past decade
  od: Kirkwood John M, i dr.
  Izdano: (2008-10-01)
• Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study
  od: Yu Du, i dr.
  Izdano: (2024-01-01)
• Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients
  od: Kirkwood John M, i dr.
  Izdano: (2011-05-01)